VYNE logo

VYNE
VYNE Therapeutics Inc

11,170
Mkt Cap
$20.03M
Volume
129,542.00
52W High
$1.99
52W Low
$0.2805
PE Ratio
-0.92
VYNE Fundamentals
Price
$0.6183
Prev Close
$0.601
Open
$0.6066
50D MA
$0.5884
Beta
0.94
Avg. Volume
205,336.63
EPS (Annual)
-$0.6192
P/B
0.72
Rev/Employee
$57,000.00
$4.20
Loading...
Loading...
News
all
press releases
SHAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--VYNE, MASI, IBCP, and HCBN
SHAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--VYNE, MASI, IBCP, and HCBN SHAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--VYNE...
PR Newswire·5d ago
News Placeholder
More News
News Placeholder
Shareholder Alert: The Ademi Firm investigates whether VYNE Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders
Shareholder Alert: The Ademi Firm investigates whether VYNE Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders Shareholder Alert: The Ademi Firm investigates whether VYNE...
PR Newswire·4mo ago
News Placeholder
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of VYNE Therapeutics Inc. (NASDAQ: VYNE)
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of VYNE Therapeutics Inc. (NASDAQ: VYNE) $HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of VYNE...
PR Newswire·4mo ago
News Placeholder
Penny Stocks To Watch Now - December 17th
Direxion Daily TSLA Bear 1X Shares, Canopy Growth, VYNE Therapeutics, Better Choice, Rezolve AI, Bitfarms, and iRobot are the seven Penny stocks to watch today, according to MarketBeat's stock...
MarketBeat·4mo ago
News Placeholder
VYNE Stock Alert: Halper Sadeh LLC is Investigating Whether the Merger of VYNE Therapeutics Inc. is Fair to Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of VYNE Therapeutics Inc. (NASDAQ: VYNE) and Yarrow Bioscience, Inc. is fair to VYNE shareholders. Upon completion...
Business Wire·4mo ago
News Placeholder
VYNE Therapeutics Inc. (VYNE) Reports Q3 Loss, Tops Revenue Estimates
VYNE Therapeutics (VYNE) delivered earnings and revenue surprises of +10.53% and +12.67%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·5mo ago
News Placeholder
VYNE Therapeutics Inc. (VYNE) Reports Q2 Loss, Lags Revenue Estimates
VYNE Therapeutics (VYNE) delivered earnings and revenue surprises of +43.48% and -31.00%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·8mo ago
News Placeholder
Metagenomi (MGX) Reports Q2 Loss, Tops Revenue Estimates
Metagenomi (MGX) delivered earnings and revenue surprises of +20.59% and +20.50%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·8mo ago
News Placeholder
Aquestive Therapeutics (AQST) Reports Q2 Loss, Lags Revenue Estimates
Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of +22.22% and -9.62%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·8mo ago
News Placeholder
Catalyst Pharmaceutical (CPRX) Q2 Earnings and Revenues Surpass Estimates
Catalyst (CPRX) delivered earnings and revenue surprises of +17.24% and +5.30%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·8mo ago
<
1
2
...
>

Latest VYNE News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.